GleamWall
中文EN

TOVX Theriva Biologics, Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 894158 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY66.7%
TTM EPS YoY-44.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-99.8%
ROA-28.0%
ROIC (approx.)-956.5%
Asset turnover—

Leverage & solvency

Liabilities / assets65.9%
Debt / equity0.00x
Current ratio1.21x
Interest coverage-138.77x

Cash quality & payout

Operating cash flow / net income1.29x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue——
R&D expense$8.60M$12.03M
SG&A expense$15.45M$7.40M
Operating income-$24.05M-$26.35M
Interest expense$61,000$6,000
Pretax income-$23.74M-$25.65M
Income tax—$0
Net income-$23.74M-$25.65M
EBITDA-$23.94M-$26.21M
EPS (basic)-2.08-19.03
EPS (diluted)-2.08-19.03
Weighted avg. shares (diluted)12.14M1.35M
Balance sheet
Cash & equivalents$13.06M$11.71M
Current assets$17.47M$16.28M
PP&E, net$222,000$270,000
Goodwill—$0
Intangibles$19.62M$17.36M
Total assets$38.24M$35.35M
Current liabilities$10.01M$7.58M
Long-term debt$1.67M$92,000
Total debt$1.67M$92,000
Total liabilities$22.86M$16.29M
Shareholders' equity$15.38M$19.07M
Net debt-$11.38M-$11.61M
Shares outstanding35.69M2.78M
Cash flow statement
Operating cash flow-$16.67M-$16.94M
Capital expenditure$35,000$1,000
Free cash flow-$16.70M-$16.94M
Investing cash flow-$35,000-$1,000
Financing cash flow$18.19M$5.50M
Depreciation & amortization$108,000$137,000
Stock-based compensation$654,000$671,000

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.